Actively Recruiting
Open-Label Study of Cannabidiol Oral Solution for Focal-Onset Seizures in Participants Aged 12 to 75 Years
Led by Jazz Pharmaceuticals · Updated on 2026-10-29
100
Participants Needed
24
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of cannabidiol oral solution CBD-OS on focal-onset seizures in participants aged 12 to 75 years. This phase 1b open-label study aims to assess how CBD-OS reduces seizure frequency and impacts health outcomes in both early line and treatment-resistant focal seizure patients. The study also investigates safety, pharmacokinetics, and factors influencing treatment response through brain imaging and neuropsychological tests in a substudy. Participants will receive open-label CBD-OS according to the approved local dosing guidelines. The study monitors participants who are on stable antiseizure medication regimens, and treatment response will be compared to baseline seizure frequency. This trial is designed as a single-group study without placebo or comparator arms. During the study, participants will have their focal seizure counts tracked and compared to baseline over a period of up to 16 weeks. Evaluations include safety assessments, pharmacokinetic sampling, functional MRI, and neuropsychological testing for a subset of participants. The total study duration spans from screening through treatment and monitoring until study completion, with ongoing safety and efficacy evaluations.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Research Team
C
Clinical Trial Disclosure & Transparency
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here